Stocktoria
Korro Bio, Inc. KRRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-03
Korro Bio, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Operating margin | -1906.4% | -4047.1% | — | — | — |
| Net margin | -1834.5% | -3680.4% | — | — | — |
| FCF margin | -1237.2% | -3433.6% | — | — | — |
| Return on assets | -103.3% | -36.9% | -36.6% | — | — |
| Return on equity | -228.0% | -52.1% | -47.8% | — | — |
| Current ratio | 6.90 | 8.79 | 8.87 | 4.42 | 5.81 |
| Revenue growth | 181.5% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001703647 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.